Notably, the GCC2 levels were significantly high in patients with early-stage (T1aN0-T1bN0) lung cancer, which suggests that plasma-derived exosomal GCC2 protein level could be a feasible, valuable, and non-invasive biomarker for the early diagnosis of lung cancer. Here, GCC2 is linked to lung cancer.